Sage Therapeutics’ SAGE phase II study evaluating its neuropsychiatric candidate, dalzanemdor (SAGE-718), for treating cognitive impairment (CI) associated with Huntington’s Disease (HD) failed to...
The S&P 500 Index ($SPX ) (SPY ) Wednesday closed down -0.74%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -1.06%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.70%. US stock...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.51%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.81%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.36%. US stock indexes today are...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.62%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.88%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.50%. US stock indexes today are...
A secondary stock sale and underwhelming quarterly results sent investors to the off-ramp.
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE). Such...
The pharmaceutical company's growth prospects have taken a big hit.
/PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Sage...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE). Such...
The company got bad news from the FDA and saw increased losses.